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Abstract
Background: There have been conflicting reports of the role of Type I interferons (IFN) in inflammatory bowel disease (IBD).
Clinical trials have shown potent efficacy of systemic interferon-beta (IFN-b) in inducing remission of ulcerative colitis.
Likewise, IFNAR1
2/2 mice display an increased sensitivity to dextran sulfate sodium (DSS)-induced colitis, suggesting Type I
IFN play a protective role during inflammation of the gut. Curiously, however, there have also been reports detailing the
spontaneous development of IBD in patients receiving systemic IFN-b therapy for multiple sclerosis or hepatitis.
Methodology/Principal Findings: To investigate the effects of local administration of IFN-b on a murine model of colitis, we
developed a transgenic Lactobacillus acidophilus strain that constitutively expresses IFN-b (La-IFN-b). While pretreatment of
mice with control Lactobacillus (La-EV) provided slight protective benefits, La-IFN-b increased sensitivity to DSS. Analysis
showed colitic mice pretreated with La-IFN-b had increased production of TNF-a, IFN-c, IL-17A and IL-13 by intestinal tissues
and decreased regulatory T cells (Tregs) in their small intestine. Examination of CD103
+ dendritic cells (DCs) in the Peyer’s
patches revealed that IFNAR1 expression was dramatically reduced by La-IFN-b. Similarly, bone marrow-derived DCs
matured with La-IFN-b experienced a 3-fold reduction of IFNAR1 and were impaired in their ability to induce Tregs.
Conclusions/Significance: Our IFNAR1 expression data identifies a correlation between the loss/downregulation of IFNAR1
on DCs and exacerbation of colitis. Our data show that Lactobacillus secreting IFN-b has an immunological effect that in our
model results in the exacerbation of colitis. This study underscores that the selection of therapeutics delivered by a bacterial
vehicle must take into consideration the simultaneous effects of the vehicle itself.
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Introduction
Type I interferons (IFN), including IFN-a and IFN-b, are
widely expressed cytokines involved in innate anti-viral immune
responses. Additionally, these cytokines have an immunomodula-
tory role in the anti-inflammatory host response. Type I IFN signal
through a heterodimeric receptor complex comprised of two
subunits, IFNAR1 and IFNAR2. When IFN-a/b bind to the
IFNAR1/2 complex, there is recruitment and subsequent
phosphorylation of STAT1 and STAT2 [1].
The anti-inflammatory properties of Type I IFN have been
recognized in human diseases, such as multiple sclerosis (MS) [2].
AdministrationofType I IFNinmousemodelsleads toreducedskin
reactivitytolipopolysaccharides(LPS),reduced responsetoischemic
insult/chemokine injection, and protection from collagen-induced
arthritis (CIA), experimental autoimmune encephalomyelitis (EAE)
and delayed-type hypersensitivity-allotransplant rejection (reviewed
in [3]). In the CIA model, IFN-b prevented the onset of arthritis or
ameliorated existing disease by suppressing the proinflammatory
mediators IFN-c, IL-6, IL-12 and TNF-a and by inducing the anti-
inflammatory cytokine IL-10 [4,5]. Additionally, Type I IFN can
suppress inflammatory responses by stimulating tristetraprolin, a
strong suppressor of TNF-a and IFN-c [6,7], or by inhibiting
CXCL8, a chemokine that recruits neutrophils and leukocytes to
areas of inflammation [8,9].
The anti-inflammatory properties of IFN-b are perhaps best
recognized and studied in MS, a chronic inflammatory disorder of
the central nervous system. As a standard therapy for relapsing
remitting MS, the mechanisms of IFN-b action have been widely
studied. It has been shown that IFN-b inhibits expression of
adhesion molecules on the surface of endothelial cells and may
lead to reduced adhesion of leukocytes and attenuation of
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downregulate matrix metalloproteinases that are implicated in the
immunopathogenesis of MS [12,13]. Although Th1 cells are
involved in the autoimmune inflammation in MS and in the
mouse model EAE, IL-17-secreting T cells have been shown to
play a pivotal role in the pathogenesis of the disease [14–16].
Recently, studies have shown that IFN-b inhibits Th17 cell
differentiation, which may help explain its therapeutic benefits in
MS [17–19].
The anti-inflammatory abilities of Type I IFN have also been
investigated in ulcerative colitis (UC), an inflammatory bowel
disease (IBD) that causes ulcers in the lining of the colon and
rectum. There have been several clinical trials in UC patients that
have shown efficacy of systemic administration of IFN-b, with up
to 88% remission in patients with steroid-refractory UC [20–22].
Curiously, there have been reports of exacerbation or spontaneous
development of IBD, such as Crohn’s disease and UC, in patients
receiving IFN-a/b therapy for chronic hepatitis or MS [23–27].
Thus, the mechanism mediating this paradoxical effect of IFN-b in
vivo warrants further investigation.
In recent years, research into the pathogenesis of gut
inflammation has revealed Th17 cells as central effectors that
produce proinflammatory cytokines including IL-17 [28–30].
Given the ability of IFN-b to inhibit Th17 cells in EAE, there is
a need to investigate the role of IFN-b in Th17-mediated gut
inflammation. One study showed that in dextran sulfate sodium
(DSS)-induced colitis, IFN-b offers protective benefits when
induced via TLR9 and when administered in recombinant form
during the course of colitis [31], although the effect on IL-17
expression was not reported. One human UC study showed a
correlation between response to Type I IFN therapy and
suppression of IL-17 production and Th17 differentiation [32].
However, there is a lack of understanding of how IFN-b may
abrogate intestinal inflammation and whether it can specifically
counteract Th17 in this context.
Based on its anti-inflammatory properties and previous success
in colitis studies, we investigated the effects of IFN-b in a murine
colitis model. Systemic administration of IFN-b often results in flu-
like symptoms and is generally not well tolerated. Previous work
has shown efficacy in localized delivery of therapeutics in colitis
models via lactic acid bacteria [33–35]. This approach avoids
systemic toxicity associated with cytokine-based therapies and
offers delivery directly to inflamed mucosal tissue. In this study, we
developed a genetically modified bacterium, Lactobacillus acidophilus,
that constitutively expresses IFN-b. Using these transgenic
bacteria, we employed a pretreatment model of acute DSS-
induced colitis where mice were administered Lactobacillus secreting
IFN-b (La-IFN-b) or an empty vector control (La-EV). Surpris-
ingly, our data show that pretreatment with La-IFN-b exacerbates
DSS colitis, with an increase in TNF-a, IFN-c, IL-17A and IL-13
production by intestinal tissues over the controls.
Materials and Methods
Cells and mice
Ethics statement: Mice were bred and maintained in specific
pathogen-free conditions in accordance with the procedures
outlined in the ‘‘Guide for Care and Use of Laboratory Animals’’
(National Institute of Health, Bethesda, MD, 1996). All animal
studies were approved by the Animal Care and Use Committee
under the protocol ID 09-027 at the National Cancer Institute,
NIH USA. A/JCr, C57BL/6Ncr and BALB/cAnNcr mice were
purchased from Charles River Laboratories (Wilmington, MA).
IFN-a/b receptor 1 (IFNAR1)-deficient mice (BALB/c-alpha-R
KO) were provided by Joan Durbin (Ohio State University,
Columbus, OH). All mice were analyzed between 8–12 weeks of
age. The C57BL/6 murine macrophage cell line was derived as
previously described [36] and grown in DMEM (BioWhittaker,
Walkersville, MD) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA),
penicillin (100 U/ml), streptomycin (100 mg/ml) and L-glutamine.
Expression vector and bacteria
Lactobacillus acidophilus NCK 1887 containing the vector
pTRK926 (termed La-IFN-b), which constitutively expresses
murine IFN-b, was used as a localized delivery method of IFN-b
to mice prior to induction of DSS colitis. L. acidophilus NCK 1895
containing the vector pTRK882 [37] (termed La-EV), which does
not have the murine IFN-b gene inserted, was used as an empty
vector control. The murine IFN-b gene was codon optimized
(website: www.jcat.de/) for expression in Lactobacillus and then
cloned into the pTRK882 plasmid to generate pTRK926. The
expression of IFN-b in this vector is under the control of the
constitutive high-expressing promoter Ppgm. Lactobacillus cultures
were grown statically in sealed conical tubes in deMann, Rogosa,
and Sharpe (MRS) broth (BD Difco, Franklin Lakes, NJ) at 37uC,
with 5 mg/ml of erythromycin (Sigma-Aldrich). Solid media for
plating was prepared with 1.5% agar (BD Difco) and 5 mg/ml of
erythromycin. Bacterial plates containing Lactobacillus were grown
in anaerobic bags for 48 h (Bio-Bag Type A; BD Biosciences, San
Jose, CA). For gastric gavage of mice, bacteria were grown until
log-phase (based on growth curves), washed twice with PBS and
resuspended to achieve 4610
9 CFU/ml. Mice were subjected to
gastric gavage with 250 ml of PBS or the bacterial strains
(1610
9 CFU/mouse/gavage). Quantification of bacterial CFU
was performed on probiotic preparations by plate count method,
and mouse feces were checked daily for the presence of the
transgenic Lactobacillus.
Bone-marrow derived dendritic cell experiments
Murine bone marrow-derived dendritic cells (BMDCs) were
generated from mice as previously described [38]. Briefly, bone
marrow cells were grown in RPMI 1640 (BioWhittaker)
supplemented with 10% heat-inactivated FBS, penicillin (100 U/
ml), streptomycin (100 mg/ml), L-glutamine, 1 mM sodium
pyruvate, 1 mM NEAA, 10 mM HEPES, 50 mM b-mercaptaetha-
nol, IL-4 (10 ng/ml) and GM-CSF (20 ng/ml). On day 2
following plating, non-adherent cells were removed from the
culture. On day 4 cells were washed and plated in fresh media and
on day 6 the BMDCs were harvested. BMDCs from wild-type or
IFNAR1
2/2 were matured with 1000 U/ml of IFN-b (PBL
InterferonSource, Piscataway, NJ) or 100 ng/ml of LPS (Sigma-
Aldrich, St. Louis, MO) for 24 h before analysis. BMDCs from A/
J mice were matured with TNF-a (50 ng/ml), TNF-a + La-EV
(100:1 ratio, La-EV:BMDCs) or TNF-a + La-IFN-b (100:1 ratio,
La-IFN-b:BMDCs) for 48 h prior to co-culture with CD3/CD28
(1 mg/ml each; BioLegend, San Diego, CA) activated splenocytes
at a 1:2 ratio for 7 d.
Western blot analysis
To check for IFN-b expression/secretion, supernatants of
overnight bacterial cultures were collected and subjected to
trichloroacetic acid (TCA) protein precipitation. Briefly, 0.5 mlo f
100 mM PMSF, 1 ml of 1 M DTT and 300 ml of 100% TCA was
added to 1.5 ml of cell-free bacterial supernatant, vortexed and
held on ice for 30 min. Supernatants were then centrifuged at 4uC
at 14,000 rpm for 5 min, washed twice with cold acetone and
dried on a 95uC heat block for 5 min. 1 ml of 1 M DTT, 5 mlo f
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were added to the pellet and boiled for 10 min. Samples were run
on an SDS–polyacrylamide (Invitrogen) gel and transferred to
Immobilon-P membranes (Millipore, Billerica, MA). The mem-
branes were blocked at room temperature in 5% milk/Tris-
buffered saline Tween 20 solution. The membranes were then
probed with anti-murine IFN-b (1:1000; BioLegend) and devel-
oped with HRP substrate (Amersham Biosciences, Piscataway,
NJ).
DSS-induced colitis model
C57BL/6Ncr and A/J mice were given 3% DSS (MW 36,000–
50,000; MP Biomedicals, Solon, OH) dissolved in reverse osmosis
water ad libitum for 7 d (i.e., one cycle of DSS). Gastric gavages of
PBS or bacterial treatments (1610
9 CFU/mouse/gavage) were
given for three consecutive days prior to the administration of
DSS. For quality control, cultures used for gavages were checked
for the presence of IFN-b. On day 8, mice were returned to
normal drinking water and sacrificed on day 10. Mice were
weighed daily, checked for diarrhea and rectal prolapse/
macroscopic bleeding. The colon was assessed macroscopically
and given a semi-quantitative score (0–3) based on the degree and
extent of mucosal hemorrhaging.
Isolation of intestinal lymphocytes
Small intestinal intraepithelial lymphocytes (smIELs) were
isolated as previously described [39]. Briefly, small intestines were
harvested from mice, flushed and cleaned with HBSS (BioWhit-
taker) containing 2.5% FBS (complete media, CM). The Peyer’s
patches (PPs) were isolated from small intestines and mechanically
processed through a 100 mm cell strainer (BD Biosciences) for a
single cell suspension. Mesenteric lymph nodes (MLNs) were
processed similarly. The small intestines (with Peyer’s patches
removed) were incubated in CM in the presence of 1 mM DTT
(Sigma-Aldrich) at 37uC and 250 rpm for 20 min and subse-
quently in 1.3 mM EDTA (Boston BioProducts, Ashland, MA) in
CM at 37uC for 1 h at 250 rpm. After each incubation the
supernatant fraction containing the smIELs was strained through a
100 mm strainer and pooled. The cells were strained twice more
through 40 mm strainers and washed in CM twice before staining
for FACS analysis.
Quantification of cytokine production in sera and colonic
culture supernatants
Two cm of the distal colon was harvested from colitic mice,
weighed and cultured overnight in RPMI 1640 supplemented with
10% heat-inactivated FBS, penicillin (100 U/ml), streptomycin
(100 mg/ml), L-glutamine and Amphotericin B (1 mg/ml). Cyto-
kine levels were standardized for 100 mg of colonic tissue. Murine
IFN-c, IL-6, IL-10, IL-12p70, IL-17A, MCP-1 and TNF-a were
measured using a cytometric bead array (CBA) kit according to the
manufacturer’s instructions (BD Biosciences). BMDC cell-free
supernatants were tested for murine IL-4 and IL-6 using a Th1/
Th2 CBA kit according to the manufacturer’s instructions (BD
Biosciences). Murine IL-27p28 and IL-23 levels were determined
in cell-free supernatants by a specific ELISA kit (Quantikine; R&D
Systems).
RNA isolation, RT-PCR and focused array
Sections of the distal colon were isolated from colitic mice and
snap frozen in liquid nitrogen for RNA analysis. The tissue was
dissociated with 1.0 mm glass beads using a mini-beadbeater
(Biospec) in Trizol (Invitrogen) and RNA extraction was
performed according to the manufacturer’s instructions. The
RNA was reverse transcribed to cDNA (Invitrogen) and relative
quantification was performed by real-time PCR (RT-PCR) for IL-
17A and Foxp3 using HPRT as endogenous control according to
the manufacturer’s instructions and analyzed by DataAssist V2
(ABI). A focused array (Lonza, Cologne, Germany; Mouse
Cytokines and Receptors 00189699) was performed on colonic
RNA according to the manufacturer’s instructions and the
results were analyzed using RealTime StatMiner software V4.0
(Integromics).
Cell stimulations and Abs used for flow cytometry
Flow cytometry was performed on single cell suspensions using
an LSRII (BD Biosciences). The following Abs for extracellular
staining were purchased from eBioscience (San Diego, CA):
CD45 (30-F11), CD3 (17A2), CD4 (GK1.5), CD25 (PC61.5),
CD11c (N418) and CD103 (2E7). Additional Abs were purchased
from BioLegend (San Diego, CA): I-A/I-E (M5/114.15.2), CD40
(3/23) and IFNAR1 (MAR1-5A3). CD11b (Mac1, M1/70) was
purchased from BD Biosciences. For intracellular analysis of
Foxp3, cells were fixed/permeabilized using the Foxp3 Staining
Buffer Set (eBioscience) according to the manufacturer’s instruc-
tions. Cells were stained for Foxp3 (FJK-16s; eBioscience). For
intracellular IFN-c cytokine analysis, cells were activated with
10 ng/ml PMA (Sigma-Alrich) and 1 mM/ml ionomycin (Sigma-
Alrich) for 5 h in the presence of Brefeldin A (eBioscience) in
RPMI 1640 supplemented with 10% heat-inactivated FBS,
penicillin (100 U/ml), streptomycin (100 mg/ml) and L-gluta-
mine. After stimulation, cells were fixed/permeabilized using a
cytofix/cytoperm kit (BD Biosciences). Cells were stained for
IFN-c (DB-1; BioLegend). For intracellular analysis of STAT1
phosphorylation, C57BL/6 macrophage cells were fixed/per-
meabilized using paraformaldehyde/methanol and stained for
Stat1 (pY701) (4a; BD Biosciences).
Statistical analysis
All statistical analysis was performed using the GraphPad Prism
software (version 5.00; GraphPad, San Diego, CA). Data are
expressed as 6 SEM. The Student two-tailed unpaired, paramet-
ric t test was used to assess statistical differences between two
experimental groups. Asterisks indicate statistical differences,
* p,0.05, ** p,0.01, *** p,0.001.
Results
IFNAR1
2/2 mice are more susceptible to DSS-induced
colitis, have less responsive DCs and decreased
regulatory T cells in their Peyer’s patches
It has been reported that IFNAR1
2/2 mice have increased
susceptibility to DSS-induced colitis [31,40]. To confirm these
findings, we administered 5% DSS in the drinking water of
BALB/c wild-type or IFNAR1
2/2 mice for 7 d. Mortality and
colonic shortening, which occurs as a result of inflammation in the
mucosa and correlates with disease severity, were greatly increased
in mice lacking IFNAR1 (Figure 1A and 1B).
In order to better understand how the lack of IFNAR1
contributes to increased intestinal inflammation, we examined
the phenotype of dendritic cells (DCs) in IFNAR1
2/2 mice as
Type I IFN have been shown to play a critical role in the
development and activation of DCs in steady state as well as
inflammatory settings [41–43]. However, one caveat to this
analysis is that these mice are systemically deficient in IFNAR1.
To investigate the phenotype of DCs in mice lacking IFNAR1,
cells from spleen and liver were isolated from wild-type and
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2/2 mice. Flow cytometric analysis showed that DCs,
defined as ClassII
+CD11c
+, from IFNAR1
2/2 had lower levels of
surface expression of CD40 co-stimulatory molecules than wild-
type controls (Figure 1C). BMDCs from IFNAR1
2/2 mice
matured with IFN-b or LPS also showed decreased surface
expression of CD40 (Figure 1C). Following maturation with LPS,
the BMDC culture supernatants were collected and assayed for
cytokines. IFNAR1
2/2 BMDCs produced lower levels of IL-10,
IL-12, IL-23 and IL-27p28 than wild-type BMDCs, however they
produced more TNF-a and IL-6 (Figure 1D). The decreased
expression of co-stimulatory molecules, in addition to an overall
decreased capacity to produce cytokines upon LPS stimulation,
suggests that DCs from IFNAR1
2/2 mice are functionally
defective.
As DCs are important in the induction of regulatory T cells
(Tregs) we investigated whether Treg populations are affected in
IFNAR1
2/2 mice. Lymphocytes from mesenteric lymph nodes
(MLNs), Peyer’s patches (PPs), small intestine (small intestinal
intraepithelial lymphocytes [smIELs]) and spleen were isolated
and analyzed by flow cytometry. Tregs were defined as
CD4
+CD25
+Foxp3
+. Strikingly, the IFNAR1
2/2 mice had
significantly decreased percentages of Tregs within the PPs
specifically (Figure 1E). The functional changes in DCs combined
with an altered intestinal Treg profile in the PPs of IFNAR1
2/2
mice and an increased sensitivity to colitis suggest a role for
Type I IFN signaling in controlling intestinal inflammation and
homeostasis.
Transgenic L. acidophilus expresses functional murine
IFN-b
The data from the IFNAR1
2/2 mice indicates Type I IFN
signaling is important for controlling intestinal inflammation. IFN-
b is routinely administered as an anti-inflammatory therapy for
MS, although systemic side effects are not well tolerated. The
novel use of lactic acid bacteria to deliver therapeutics locally was
first reported by Steidler and co-workers [34]. Using this technique
to investigate the effect of local IFN-b administration on gut
inflammation, we developed a transgenic Lactobacillus that
constitutively expresses murine IFN-b (La-IFN-b) or a control
strain (La-EV). We generated individual growth curves for each
strain for quantification of bacterial colony forming units (CFU)
and used these to determine resuspension volumes for in vitro and in
vivo experiments (Figure 2A).
Expression and secretion of the IFN-b protein into bacterial
supernatant was assessed by Western blot. IFN-b was detected in
the media from the La-IFN-b culture but was absent in the La-
Figure 1. IFNAR1
2/2 mice are more susceptible to DSS-induced colitis and have altered DC and Treg profiles. (A, B) IFNAR1
2/2 mice
experienced increased weight loss and greater degree of intestinal shortening when administered 5% DSS in their drinking water for 7 d compared to
wild-type controls (n=10). (C) DCs isolated from liver and spleen of IFNAR1
2/2 mice and BMDCs matured with IFN-b (1000 U/ml) or LPS (100 ng/ml)
for 24 h were analyzed for cell surface expression of CD40. DCs were gated as CD45
+ClassII
+CD11c
+.( D) Levels of cytokines, measured by CBA or
ELISA (IL-23 and IL-27p28), in BMDC supernatants stimulated with LPS (100 ng/ml) for 24 h from IFNAR1
2/2 or wild-type mice (n=5). (E) Percent
Tregs, gated as CD45
+CD4
+CD25
+Foxp3
+, in MLNs, PPs, smIELs and spleens of IFNAR1
2/2 and wild-type mice (ND=not detected, n=10). The data is
represented as the mean 6 SEM. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0016967.g001
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secreted IFN-b, we stimulated a C57BL/6 macrophage cell line
with recombinant IFN-b as a control and observed rapid
phosphorylation of STAT1 in a dose dependent manner (Figure
S1). Co-culture of macrophage cells with La-IFN-b also resulted
in rapid phosphorylation of STAT1 in a dose dependent manner,
while no phosphorylation was observed in co-culture with the La-
EV control in the time frame analyzed (Figure 2C). The
activation of STAT1 by La-IFN-b indicates that the secreted
IFN-b protein can bind IFNAR and initiate the STAT1 signaling
pathway.
Pretreatment with La-IFN-b exacerbates DSS-induced
colitis
To investigate the efficacy of localized delivery of IFN-b,w e
used an acute model of colitis whereby 3% DSS was administered
in the drinking water of mice for 7 d. Previous studies have
demonstrated that systemic delivery of recombinant IFN-b during
the course of DSS administration was sufficient to reduce colitis in
mice [31,40]. To study the protective capacity of La-IFN-b on
DSS-induced gut inflammation, we employed a preventative
model of therapy.
To determine the short-term duration of Lactobacillus coloniza-
tion in mice, we delivered 10
9 CFU of La-IFN-b or La-EV
control by oral gavage for 3 consecutive days. For quality control,
in all experiments involving gastric gavages the cultures were
checked for the presence of IFN-b (Figure S2A). This dosing
regimen resulted in transient colonization, with .10
7 CFU of
bacteria detected in the feces 4 d following the last gavage (data
not shown). To investigate whether the transgenic La-IFN-b
could prevent colitis induced by DSS, A/J mice were pretreated
with La-IFN-b, La-EV or PBS as a control (Figure 3A).
Pretreatment with La-EV showed no significant protective effect
by gross morphological analysis over PBS, although there was a
lesser degree of intestinal shortening (Figure 3C). Pretreatment
with La-IFN-b, however, resulted in a marked worsening of
Figure 2. La-IFN-b expresses biologically functional murine IFN-b. (A) Growth curves for La-IFN-b and La-EV strains correlating CFU/ml of
bacterial culture with OD600 values. (B) Western blot showing detection of murine IFN-b in the supernatant from an overnight culture of transgenic
La-IFN-b. Prior to Western blotting, the protein was precipitated using TCA. Positive control is 100 U of recombinant murine IFN-b.( C)
Phosphorylation of STAT1 in a C57BL/6 macrophage cell line after 60 min stimulation with rIFN-b (1000 U) as a positive control or co-culture with 5:1,
10:1, 50:1 or 100:1 ratios of La-EV or La-IFN-b.
doi:10.1371/journal.pone.0016967.g002
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cantly increased weight loss over both La-EV and PBS treated
groups, greater intestinal shortening and an increased incidence
of intestinal hemorrhaging (Figure 3B – 3D). The effect on weight
loss by pretreatment with La-IFN-b was also observed in C57BL/
6 mice, although the severity of colitis was worse in the more
sensitive A/J strain (Figure S2B). Additionally, mice in the La-
IFN-b group had the most pronounced incidence of diarrhea
with visible hemoccult (data not shown). Taken together, these
data demonstrate that pretreatment with La-IFN-b results in an
increased sensitivity to and thereby exacerbation of DSS-induced
colitis.
Increased levels of proinflammatory cytokines in colitic
mice pretreated with La-IFN-b
To study the inflammatory profile of colitic mice pretreated
with PBS, La-EV or La-IFN-b, intestinal cytokine levels were
assessed. Overnight cultures of distal colonic explants were assayed
Figure 3. Pretreatment of mice with La-IFN-b exacerbates DSS-induced colitis. (A) On days -3, -2 and -1 mice were gastric gavaged with
10
9 CFU of the bacterial treatments and days 0-7 3% DSS was administered in the drinking water. (B) Percent body weight loss of mice pretreated
with La-IFN-b, La-EV or PBS for three days. The 100% body weights were taken as the weights of mice just prior to DSS administration. Day 10 percent
body weights are plotted to show individual mice (n=10). (C) Intestinal lengths (cm) of mice on day 10 following DSS administration. Colons were
harvested and measured from the proximal end just below the cecum and to the anus (n=10). (D) Following the harvest of the colons, the tissue was
macroscopically examined for severity and distribution of intestinal hemorrhaging and scored on a scale from 0–3 (0=no visible hemorrhaging,
1=diffuse hemorrhaging, 2=widespread hemorrhaging, 3=severe hemorrhaging throughout colon). Results shown are representative of three
independent experiments.
doi:10.1371/journal.pone.0016967.g003
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TNF-a and IL-17A were increased in mice pretreated with La-
IFN-b compared to the La-EV group (Figure 4A and 4C).
Additionally, serum cytokine levels demonstrated significant
differences in TNF-a, MCP-1 and IL-6 (Figure 4B). To determine
whether differences in IL-17A could be detected at the mRNA
level, RNA was extracted from the last 2 cm of the distal colon, the
site where colitis inflammation is the most severe. The RT-PCR
data show that there is an elevation of IL-17A mRNA in the
colons of La-IFN-b pretreated mice over the La-EV controls,
consistent with the data obtained from CBA (Figure 4C).
To investigate the ability of cells from the colitic mice to
produce IFN-c, we isolated lymphocytes from MLNs and PPs and
stimulated with PMA and ionomycin for 5 h, with the addition of
Brefeldin A after 2 h. The cells were then stained for CD3 and
IFN-c and analyzed by flow cytometry. Both CD3
+ and CD3
2
populations from the MLNs and PPs had significant levels of
intracellular IFN-c. Pretreatment with La-EV significantly re-
duced the levels of CD3
+IFN-c
+ and CD3
2IFN-c
+ cells in the
MLNs compared to PBS, whereas La-IFN-b resulted in an
increase over La-EV (Figure 4D). Overall, intracellular staining of
lymphocytes revealed that the La-EV pretreatment reduced IFN-
c
+ cells in the MLNs while La-IFN-b increased IFN-c
+ cells
compared to La-EV.
The RNA isolated from the distal colon was analyzed in a
focused array for cytokines and cytokine receptors. Using
RealTime StatMiner software, the data was analyzed as genes
significantly (*p,0.1) dysregulated in the La-EV and La-IFN-b
pretreatments compared to the PBS control and plotted according
to log fold change (Table 1). 3 genes were exclusively affected by
La-EV compared to 34 by La-IFN-b and there were 12 genes
which were common to both groups. Of the genes which were
upregulated in both the La-EV and La-IFN-b groups, IL-28B and
IFN-b had the highest log fold increases, although La-IFN-b had a
much stronger effect. Additionally, IFN-a was the highest gene
exclusively upregulated by La-EV. This data confirms previous
studies which have shown that probiotics induce Type I IFN via
TLR9 signaling [31,44]. It also demonstrates the induction of high
Figure 4. Elevated levels of inflammatory cytokines in mice pretreated with La-IFN-b over La-EV. (A) 2 cm of the distal colon was
removed and weighed from colitic mice pretreated with PBS, La-EV or La-IFN-b (and a no DSS control group) and cultured overnight (n=10). IFN-c, IL-
6, IL-10, IL-12p70, MCP-1 and TNF-a cytokine levels were assayed by CBA and standardized to concentration per 100 mg tissue. (B) Serum was
assayed for the presence of inflammatory cytokines by CBA on day 7 of DSS administration (n=5). (C) Measurement of IL-17A in colonic tissue culture
(as outlined in Fig.4A) by CBA and the relative quantification of IL-17A mRNA in the distal colon was measured by RT-PCR. For RT-PCR, the colitic
groups were compared relative to a no DSS control (RQ=1) and HRPT was used as an endogenous control. (D) Cells isolated from the MLNs and PPs
of colitic mice were stimulated with PMA (10 ng/ml) and ionomycin (1 mM/ml) for 5 h with the addition of Brefeldin A after 2 h. The cells were then
stained for CD3 and fixed for intracellular detection of IFN-c. Data is presented as %CD3
+IFN-c
+ or %CD3
2IFN-c
+ cells in the CD45
+ population. The
data is represented as the mean 6 SEM. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0016967.g004
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many inflammatory cytokines upregulated exclusively by La-IFN-
b. Those that were upregulated by 1 log fold or higher include IL-
9, IL-13, IL-4, IL-17A, IL-5, IL-24, IFN-c, IL-10, IL-11, and IL-
27, many of which are known cytokines involved in the
pathogenesis of colitis. This upregulation is in comparison to
PBS treated colitic mice and thus, demonstrates profound
induction of these genes by La-IFN-b in this colitis model. The
.2.5 log fold increase of IFN-a and IFN-b by La-EV verifies a
role for Type I IFN in the protection conferred by this probiotic
treatment and supports our initial hypothesis that IFN-b may aid
in protection from colitis.
IFNAR1 is differentially expressed on CD103 DCs in the
gut
Previous reports have demonstrated the capacity of CD103
+
DCs in the gut to drive expansion of Tregs whereas CD103
2 DCs
are responsible for driving Th17 development [45–48]. As
IFNAR1 is important in DC maturation and function, we sought
to first investigate the distribution of CD103
+ and CD103
2 DC
populations in steady state conditions. We performed isolations of
lymphocytes from MLNs, PPs and smIELs and analyzed the DC
populations by flow cytometry. DCs were gated as CD45
+Clas-
sII
+CD11c
+CD11b
+ and then percentages of CD103
+ and
CD103
2 cells were determined (Figure S3A). The population
distribution of CD103
+ and CD103
2 DCs in the MLNs and
smIELs were similar, with a 3 fold higher percentage of CD103
2
DCs than CD103
+ (Figure 5A). The PPs had the highest
percentage of CD103
+ DCs compared with the other tissues, but
the CD103
2 population was still higher than CD103
+ as in the
MLNs and smIELs. When we determined the mean fluorescence
intensity (MFI) of IFNAR1 expression on the CD103
+ and
CD103
2 populations, we discovered that the CD103
+ DCs had a
2 fold higher expression of IFNAR1 compared with CD103
2 DCs
in MLNs and PPs (Figure 5B). However, IFNAR1 expression on
CD103
+ and CD103
2 DCs was equivalent in the smIELs.
IFNAR1 expression is decreased on CD103
+ DCs in colitic
mice pretreated with La-IFN-b
To determine whether La-EV or La-IFN-b treatment has an
effect on CD103 DC populations, we analyzed DCs isolated from
colitic mice. The percentage of CD103
+ DCs was slightly
increased in the La-EV group in the smIELs (Figure 5C) but
was unchanged in the MLNs and PPs (data not shown).
Additionally, there was a significant decrease in CD103
2 DCs
in the smIELs with La-EV and a corresponding slight increase
with La-IFN-b pretreatment. When we looked at IFNAR1
expression on these DC subsets, we found that IFNAR1 was
significantly decreased on CD103
+ DCs in the PPs in the La-IFN-
b group compared with both PBS and La-EV (Figure 5D).
Furthermore, there was a trend towards decreasing IFNAR1
expression in the MLNs and smIELs on CD103
+ DCs as well in
mice pretreated with La-IFN-b. We observed no differences in
IFNAR1 expression on CD103
2 DCs (data not shown).
As the colitic mice were pretreated with the bacteria 10 d prior
to the analysis of the DCs in the gut, we wanted to see the effect on
IFNAR1 expression directly after the mice were gavaged. Groups
of healthy mice were dosed with PBS, La-EV or La-IFN-b for 3
consecutive days and the CD103 DC populations in the MLNs,
PPs and smIELs were analyzed on day 4. We observed no
differences in the percentages of the CD103 populations in any of
the tissues analyzed (data not shown). However, when we
examined the levels of IFNAR1 expression in the groups, we
saw a striking decrease in the receptor expression on CD103
+ DCs
in the PPs of mice treated with La-IFN-b (Figure 5E). This data
provides a snapshot of what the receptor expression would have
been on CD103
+ DCs in the PPs just prior to initiating colitis.
Furthermore, it shows that from just after bacterial treatment
Table 1. Genes significantly* dysregulated compared to PBS
control.
La-EV only genes Shared genes
Gene Log fold p-value La-EV La-IFN-b
Ifna1 2.826 0.059 Gene Log fold p-value Gene Log
fold
p-
value
Il4ra 22.323 0.059 Il28b 2.899 0.059 Il28b 3.203 0.006
Ccr7 21.690 0.059 Ifnb1 2.572 0.096 Ifnb1 3.041 0.012
Il3 2.286 0.069 Il3 2.437 0.012
La-IFN-b only genes Il19 1.854 0.059 Ccr3 2.254 0.006
Gene Log fold p-value Ccr3 1.834 0.059 Il2 2.176 0.006
Il9 3.120 0.011 Il23r 1.725 0.059 Il23r 2.102 0.006
Il13 2.682 0.020 Il25 1.474 0.069 Il12b 1.961 0.006
Il18r1 2.109 0.014 Il2 1.420 0.067 Il25 1.891 0.006
Il9r 1.906 0.010 Il12b 1.357 0.069 Il17f 1.666 0.010
Il4 1.842 0.010 Il6 1.354 0.096 Il6 1.511 0.014
Il17a 1.827 0.013 Il17f 1.218 0.069 Il19 1.484 0.034
Il5ra 1.776 0.014 Il11ra1 21.317 0.069 Il11ra1 20.784 0.078
Il5 1.692 0.010
Cxcr2 1.606 0.010
Ccr8 1.540 0.010
Il24 1.432 0.010
Cxcl2 1.423 0.012
Ifng 1.413 0.013
Il21 1.364 0.020
Csf3 1.300 0.014
Il10 1.266 0.014
Il6ra 1.228 0.014
Il11 1.217 0.014
Il27 1.186 0.024
Ccl1 1.112 0.019
Ccr1 1.108 0.029
Ccr4 1.051 0.025
Il2ra 0.902 0.074
Lifr 0.791 0.073
Ccr5 0.783 0.066
Csf2 0.699 0.097
Il1a 0.679 0.090
Tgfb1 20.735 0.082
Il1rn 20.751 0.079
Ccl28 20.764 0.091
Il10rb 20.783 0.086
Il18 20.792 0.086
Il6st 21.258 0.014
Shown are the fold changes in genes which were significantly* (p,0.10)
dysregulated in colitic mice (n=3/group) pretreated with La-EV or La-IFN-b
compared to the PBS control.
doi:10.1371/journal.pone.0016967.t001
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significantly lower on the CD103
+ DCs in the PPs in the La-IFN-b
mice than in the other groups.
Our previous data showed a link between the lack of IFNAR1
and the reduction of Tregs in the PPs (Figure 1E). Thus, we
examined whether the pretreatments had an effect on the Treg
populations in the intestinal tissues of the colitic mice. There was
no difference in the percentages of Tregs in the MLNs or PPs
between groups. However, there was a significant increase in
Tregs in the smIELs of mice pretreated with La-EV over PBS and
a significant decrease in Tregs in the La-IFN-b group compared to
La-EV (Figure 5F). As isolations of lymphocytes from the large
intestines did not yield enough cells to carry flow cytometric
analysis, we examined potential differences in Tregs in this tissue
by performing RT-PCR for Foxp3. We did not detect any
differences in Foxp3 mRNA between the treatment groups in the
large intestines, although DSS itself caused a 4-6 fold increase
(Figure S3B).
Maturation of BMDCs with La-IFN-b results in significantly
lower expression of IFNAR1 and CD40 as well as an
impaired ability to induce Tregs
To investigate the direct effect that La-IFN-b has on DCs, we
isolated bone marrow from A/J mice and derived DCs using IL-4
and GM-CSF. We then matured the BMDCs with TNF-a or a
combination of TNF-a + La-EV or TNF-a + La-IFN-b for 2 d.
The matured BMDCs were then co-cultured with CD3/CD28-
activated splenocytes for 7 d at a ratio of 1:2 (BMDCs:splenocytes).
After co-culture, the cells were stained for analysis of DCs and
Tregs. The BMDCs matured with TNF-a + La-IFN-b resulted in
an increased percentage of CD11c
+ClassII
+ cells compared to
Figure 5. IFNAR1 is decreased on CD103
+ DCs in the PPs of mice following treatment with La-IFN-b. (A) Percent distribution of CD103
+
versus CD103
2 DCs in the MLNs, PPs and smIELs of wild-type mice (n=5) gated on CD45
+ClassII
+CD11c
+CD11b
+ cells. (B) IFNAR1 expression (mean
fluorescence intensity, MFI) on CD103
+ and CD103
2 DCs in the MLNs, PPs and smIELs from wild-type mice. (C) CD103
+ and CD103
2 DC percentages
in the smIELs of colitic mice pretreated with PBS, La-EV or La-IFN-b (n=5). (D) IFNAR1 expression (MFI) on CD103
+ DCs in the MLNs, PPs and smIELs of
colitic mice in the different treatment groups. (E) IFNAR1 expression on CD103
+ DCs in the PPs of healthy mice following three consecutive days of
gastric gavage with PBS, La-EV or La-IFN-b.( F) Cells were isolated from colitic mice pretreated with PBS, La-EV or La-IFN-b (n=5) from the MLNs, PPs
and smIELs and stained for the presence of Tregs, which were gated as CD45
+CD4
+CD25
+Foxp3
+. The graph shows the % Tregs present in the CD45
+
population. (G, H) BMDCs from wild-type mice were matured with TNF-a (50 ng/ml), TNF-a + La-EV or TNF-a+ La-IFN-b (100:1 ratio, bacteria:BMDCs)
for 2 d. The mature BMDCs were then co-cultured with CD3/CD28 (1 mg/ml) activated splenocytes for 7 d (1:2 ratio, BMDCs:splenocytes). Following
co-culture, DCs (gated as ClassII
+CD11c
+) were stained for CD40 and IFNAR1 expression (G) and the percent Tregs (CD4
+CD25
+Foxp3
+) was
determined (H). The data is represented as the mean 6 SEM. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0016967.g005
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stimulatory molecule CD40 was significantly reduced on BMDCs
matured with TNF-a + La-IFN-b (Figure 5G). Interestingly, there
was a dramatic decrease in IFNAR1 expression on the BMDCs
matured with TNF-a + La-IFN-b. However, there was also a
reduction by TNF-a + La-EV compared with TNF-a alone, most
likely as a result of autocrine TLR-induced IFN-b signaling. The
co-culture with the activated splenocytes yielded a significantly
increased percentage of Tregs by TNF-a + La-EV-matured
BMDCs, while there was a very significant reduction in the
percentage of Tregs by TNF-a + La-IFN-b BMDCs (Figure 5H).
Thus, although IFNAR1 was reduced by TNF-a + La-EV there
was still a positive effect on the induction of Tregs while a greater
loss of IFNAR1 induced by TNF-a + La-IFN-b had a negative
effect on Tregs. This suggests that the robustness of IFN-b
signaling and subsequent IFNAR1 depression are important
factors in DC activation and function.
Discussion
There is significant scientific data to support a role for the
intestinal microflora in maintaining intestinal homeostasis and/or
contributing to intestinal inflammation [49–51]. Probiotic thera-
pies are being widely investigated for their ability to attenuate
IBD, such as UC. Additionally, transgenic lactic acid bacteria have
been used to study the localized effects of therapies on gut
inflammation in experimental colitis models and have been tested
in human clinical trials with some success [52].
In the intestinal tract, bacteria, such as Lactococcus sp. and
Lactobacillus sp., can trigger TLRs on DCs which in turn induces
Type I IFN. Blockade of either TLR9 signaling or IFNAR1
inhibits the protective capability of TLR9 agonists, such as
probiotics, in murine colitis [31,40,44]. A previous study showed
that pretreatment of mice with CpG-ODN, a TLR9 ligand,
protected from DSS-induced colitis by the induction of Type I
IFN [53]. The protective benefits of TLR9-induced Type I IFN
are thought to be mainly mediated by TLR9 activation in
conventional DCs (cDCs), as depletion of cDCs abolished the anti-
inflammatory effects of pretreatment with CpG-ODN [31,40].
Additionally, L. acidophilus has been shown to induce IFN-b
production by DCs in vitro by a TLR2 dependent mechanism [54].
Moreover, it is well documented that probiotics, such as L.
acidophilus, induce Type I IFN via TLR stimulation and studies in
experimental colitis suggest that this provides a protective benefit.
Studies on mice lacking IFNAR1 have demonstrated the
importance of Type I IFN in the in vivo turnover, proliferation
and trafficking of DCs [55]. Furthermore, IFNAR1 defective DCs
have a diminished ability to stimulate naı ¨ve T cell proliferation
[56]. We have shown that splenic and hepatic IFNAR1
2/2 DCs
have lower expression of CD40 and that BMDCs derived from
IFNAR1
2/2 mice produce lower levels of cytokines upon LPS
stimulation. Additionally, as we and others have shown,
IFNAR1
2/2 mice are more susceptible to DSS-induced colitis.
The reasons behind this increased sensitivity still need to be more
thoroughly examined, although we have shown in this study that
IFNAR1
2/2 mice have a significantly reduced percentage of
Tregs in the Peyer’s patches.
Given the protective benefits of TLR9-induced Type I IFN in
experimental colitis and reported success of recombinant IFN-b
therapy in human colitis, we have developed a transgenic
Lactobacillus strain that constitutively expresses murine IFN-b.
We investigated whether localized administration of IFN-b by this
bacterium could protect from experimental colitis. Surprisingly,
the data from our study indicate that La-IFN-b exacerbates
DSS-induced colitis compared to La-EV and PBS. Pretreatment of
mice with La-EV prior to the administration of DSS had a slight
protective effect as demonstrated by reduced levels of proin-
flammatory cytokines and an increased percentage of Tregs in the
smIELs compared to the PBS control group. Interestingly, La-EV
induced high levels of IL-28B production in colonic tissue, in
addition to IFN-a and IFN-b; induction of IL-28B by Lactobacillus
has not yet been reported. Pretreatment with La-IFN-b, however,
resulted in significantly increased weight loss, greater intestinal
shortening and an increased incidence of intestinal hemorrhaging.
Furthermore, La-IFN-b pretreated mice had increased levels of
proinflammatory cytokines, such as IL-17A and IL-13, and a
lower percentage of Tregs in the smIELs. Taken together, our data
demonstrate that mice pretreated with La-IFN-b experienced
increased sensitivity to DSS.
To further investigate why La-IFN-b pretreatment exacerbated
colitis, we focused our attention on CD103 DCs. As mentioned,
IFNAR1 signaling plays an important role in DC development
and function. A recent study has shown that Type I IFN signaling
on splenic CD8
+ DCs, in particular, enhances the turnover of
these cells in vivo [55]. The analogous DC subset found in the
intestine is CD103
+ DCs and recent reports have highlighted the
importance of these cells in colitis. Within the gut, DCs are central
mediators of T cell skewing and activation, and thus they are
important in controlling gut-associated inflammation by inducing
either inflammatory Th17 cells or Tregs. CD103
+ DCs are
important in driving Treg proliferation whereas CD103
2 DCs are
involved in the production of proinflammatory cytokines and
Th17 development [57–60]. To investigate the role of Type I IFN
on these subsets and whether they may be involved in the
exacerbation of colitis seen in our model, we first isolated gut-
associated lymphocytes from wild-type mice. We characterized the
distribution of CD103
+ and CD103
2 DCs in the MLNs, PPs and
smIELs. The CD103
2 DC population was predominant in all of
these tissues; however, there was a higher percentage of CD103
+
DCs in the PPs compared to the MLNs and smIELs. Analysis of
these populations in our DSS pretreatment model revealed that
there was a slight increase of CD103
+ DCs and a significant
decrease of CD103
2 DCs in the smIELs of mice treated with La-
EV compared to the PBS control. This increase/decrease of
CD103
+ and CD103
2 populations, respectively, in the smIELs in
the La-EV group may be playing a role in the slight protective
effects seen in our model because, notably, the smIELs was the
only tissue we analyzed which showed an increase in Tregs by this
treatment. However, we did not detect striking differences in the
CD103 DC populations in the La-IFN-b group, suggesting
perturbation of these DC subsets is not playing a role in the
exacerbation by La-IFN-b.
The susceptibility of IFNAR1
2/2 mice to DSS-induced colitis
suggests that the expression of this receptor is important in
protection against gut inflammation. Although we did not see a
difference in the percent distributions of CD103 DCs populations
in the La-IFN-b group, we sought to determine whether
pretreatment might have an effect on the expression of IFNAR1.
Interestingly, analysis of CD103 DCs in wild-type mice revealed
that IFNAR1 is more highly expressed on CD103
+ DCs in the
MLNs and PPs than on CD103
2 DCs, suggesting that IFNAR1
signaling may play a more important role for CD103
+ DC
function than CD103
2 DCs in these tissues. Examination of
IFNAR1 expression on CD103
+ DCs from the treatment groups
in our colitis model revealed that there was a reduction in receptor
expression in mice pretreated with La-IFN-b in all of the intestinal
tissues we examined, with the most significant reduction occurring
in the PPs. Additionally, analysis of the CD103
+ DCs in the PPs of
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reduction in IFNAR1 expression by La-IFN-b. As noted, of the
gut populations we analyzed, the PPs of IFNAR1
2/2 mice showed
the most significant reduction in the percentage of Tregs, although
we did not see differences in the percentage of Tregs in the PPs of
the colitic mice at the time point we examined.
To further understand the effect of La-IFN-b on DCs and the
subsequent effect on Tregs, we derived BMDCs and matured
them with TNF-a, TNF-a + La-EV or TNF-a + La-IFN-b. The
BMDCs matured with TNF-a + La-IFN-b showed a dramatic loss
of IFNAR1 and, similar to the IFNAR1
2/2 BMDCs we
examined, had a marked reduction in the surface expression of
CD40. When these BMDCs were co-cultured with activated
splenocytes, we found that maturation with TNF-a + La-IFN-b
significantly impaired those BMDCs ability to induce Tregs.
Taken together, the IFNAR1 expression data from the colitic and
healthy mice, as well as the effect of IFNAR1 loss or
downregulation in IFNAR1
2/2 mice or in vitro cultures respec-
tively, suggest that the loss of IFNAR1 expression may correlate
with a decreased ability to generate Tregs, which in the course of
DSS colitis may ultimately lead to increased sensitization. It is
known that the binding of Type I IFN with IFNAR1/2 results in
internalization via endocytosis and degradation of the receptor
[61,62]. Interestingly, IFN-b forms a stronger and more stable
complex with IFNAR1/2 and there is a 30-fold increase in
complex lifetime over IFN-a [63,64]. The engagement of IFNAR1
by IFN-b results in a transient decrease in surface expression as the
receptors are internalized and degraded [65]. One study
demonstrated that autocrine production of IFN-b from LPS and
poly(I:C)-matured DCs caused a marked decline in the level of
IFNAR1 lasting over 24 h and consequently, the cells lose their
sensitivity to IFN-b stimulation [43]. Thus, the turnover rate of the
receptor plays a critical role in the activity of IFN-b-stimulated
DCs.
The signaling of the secreted IFN-b by La-IFN-b in addition to
the high levels of Type I IFN induced by Lactobacillus, as seen in
our expression data, may have resulted in an indirect suppression
of IFNAR1 on CD103
+ DCs in the PPs by a period of saturation
with IFN-b in the environment. The decrease of IFNAR1 surface
expression prior to induction of colitis may have inadvertently led
to the inability of IFN-b to signal during the inflammatory period.
Thus, the increased sensitivity of IFNAR1
2/2 mice to DSS may,
in effect, be mimicked in the La-IFN-b pretreated mice as a result
of decreased receptor expression, which we observed both before
and after DSS treatment. In support of this, we show that there is
increased IL-17A both in colonic supernatants and at the mRNA
level in the La-IFN-b group. Given that IFN-b has been shown to
block the development of IL-17-producing T cells and expression
of IL-17, these results indicate that IFN-b may not be signaling in
the system.
Recently Mannon and co-workers demonstrated that UC
patients who responded to IFN-b therapy had a marked reduction
in IL-13 levels, both in peripheral blood and by lamina propria T
cells [66]. IL-13, which is produced by both Th2 and NK T cells,
has been shown to play a fundamental role in the pathogenesis of
colitis and can be inhibited by Type I IFN [67–70]. In our gene
expression data, IL-13 is upregulated 2.68 log fold in colitic mice
pretreated with La-IFN-b, which again supports our conclusion
that La-IFN-b exacerbates colitis and that this may be a result of
the inability of IFN-b to signal. Interestingly, Mannon and co-
workers show that non-response of UC patients to IFN-b therapy
was associated with high baseline levels of IL-17. Taken together,
the role of Type I IFN in controlling or exacerbating gut
inflammation may be dependent upon factors intrinsic to the
patients, such as IFNAR1 expression. Likewise, this may help to
explain the spontaneous development of IBD in some patients
receiving IFN-b therapy for MS or hepatitis. However, the
underlying mechanisms for why decreased expression of IFNAR1
on DCs may promote exacerbation of colitis, whether it be
through an impaired ability to induce Tregs or an inability to
control proinflammatory cytokine expression, such as IL-17 and
IL-13, and whether the level of receptor downregulation we
observed has significant immunological effects needs to be
investigated further. Additionally, it would be of interest to study
the effects of La-IFN-b administration in other disease contexts,
such as in a DSS treatment model or other models of colitis, or to
see if the previously reported protective benefits of recombinant
IFN-b in experimental colitis is dose dependent.
Here we have reported our finding that Lactobacillus expressing
IFN-b causes an exacerbation of DSS-induced colitis. The
negative effect of this combinatory approach is the first to be
described. During the course of our investigation we discovered
that in steady state, CD103
+ DCs express higher levels of IFNAR1
than CD103
2 DCs, indicating that Type I IFN signaling may be
particularly important for this cell type. Additionally, surface
expression of IFNAR1 on CD103
+ DCs is sensitive to treatment
with La-IFN-b and may correlate with induction of Tregs.
Overall, the combination of Lactobacillus with the secreted IFN-b
in our model resulted in the exacerbation of colitis. This study
highlights the importance of why the selection of therapeutics
delivered by a bacterial vehicle must take into consideration the
immunological effects of the vehicle itself.
Supporting Information
Figure S1 Histogram showing increasing phosphorylation of
STAT1 in a C57BL/6 macrophage cell line stimulated for 60 min
with 0.5, 5, 50, 500 or 1000 U/ml of IFN-b.
(TIF)
Figure S2 (A) Western blot showing the presence of IFN-b in the
supernatants of La-IFN-b cultures, and absent in La-EV, used for
gastric gavaging of mice. Shown is a representative of this quality
control performed for all experiments. (B) Percent body weight
loss of C57BL/6 mice pretreated with PBS, La-EV or La-IFN-b
for 3 days and then administered 3% DSS in their drinking water
for 7 d. Day 8 weights are plotted separately to show individual
mice (n=10).
(TIF)
FigureS3 (A) Gatingstrategy for CD45
+ClassII
+CD11c
+CD11b
+
and CD103
+ and CD103
2 DCs in the MLNs, PPs and smIELs of
wild-type mice. IFNAR1 expression (% of max) is shown for
CD103
+ and CD103
2 DC subsets. (B) RT-PCR for Foxp3 mRNA
in the distal colon of colitic mice pretreated with PBS, La-EV or La-
IFN-b relative to a no DSS control (RQ=1). HRPT was used as an
endogenous control.
(TIF)
Figure S4 BMDCs from wild-type mice were matured with
TNF-a (50 ng/ml), TNF-a + La-EV or TNF-a + La-IFN-b (100:1
ratio, bacteria:BMDCs) for 2 d. The mature BMDCs were then
co-cultured with CD3/CD28 (1 mg/ml) activated splenocytes for 7
d (1:2 ratio, BMDCs:splenocytes). The percent of CD11c
+ClassII
+
cells were determined for each maturation treatment by
flow cytometry. The data is represented as the mean 6 SEM.
*** p,0.001.
(TIF)
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